• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Dendreon’s CSO, Dave Urdal, to retire

Dendreon’s CSO, Dave Urdal, to retire

March 15, 2011
CenterWatch Staff

David Urdal, the scientific entrepreneur who co-founded Dendreon 15 years ago and helped turn it into a pioneer of cancer immunotherapy, is stepping down from his job as chief scientific officer at the Seattle biotech company, according to Xconomy Seattle.

Urdal, 61, will retire as Dendreon’s executive vice president and chief scientist at the end of 2011, according to a regulatory filing with the Securities & Exchange Commission. He will officially hand over his duties to Mark Frohlich, chief medical officer, on Dec. 31.

Urdal made the announcement to his colleagues in-house via e-mail: “Anyone who has talked to me for more than two minutes knows that I have become bewitched, bewildered and bedazzled with the arrival of our first grandchild last April. The same month that the FDA brought us into a new era of cancer treatment with the approval of Provenge, my daughter brought the Urdal family into the next generation with the birth of my granddaughter. I look forward to seeing the world through her eyes and the eyes of the grandson we expect to see in June.”

“I am now in my sixteenth year with Dendreon and what an extraordinary journey it has been—the first autologous cellular immunotherapy approved by the FDA! What an achievement and what a pleasure it is to be a member of such a truly extraordinary team—the Dendreon team—as we won the high achievement of Provenge approval. We are just getting started.”

Dendreon CEO Mitch Gold, in his note to employees, said: “Dave has been an inspiration to so many of us, myself included. Over his many dedicated years, he has provided thoughtful leadership, helping to guide us from inception through the FDA approval of the world’s first autologous cellular immunotherapy.”

The company, which now employs about 1,500 people around the country, is worth almost $5 billion, and has a drug that could generate more than $4 billion in annual worldwide sales at its peak, according to JP Morgan analyst Cory Kasimov.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing